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Dengue fever, dengue haemorrhagic fever, and dengue shock syndrome (DF/DHF/DSS) are tropical diseases that cause signiﬁcant
humanitarian and economic hardship. It is estimated that more than 2.5 billion people are at risk of infection and more than
100 countries have endemic dengue virus transmission. Laboratory tests are essential to provide an accurate diagnosis of dengue
virus infection so that appropriate treatment and patient management may be administered. In many dengue endemic settings,
laboratory diagnostic resources are limited and simple rapid diagnostic tests (RDTs) provide opportunities for point-of-care
diagnosis. This paper addresses current issues relating to the application of commercial dengue RDTs for the diagnosis of acute
dengue virus infection, recent diagnostic evaluations, and identiﬁes future needs.
1.Introduction
1.1. The Burden of Dengue. Dengue fever, dengue haemor-
rhagic fever and dengue shock syndrome (DF/DHF/DSS)
are a group of tropical disease states that cause signiﬁ-
cant humanitarian and economic hardship. DF/DHF/DSS
are caused by the dengue virus, which belongs to the
ﬂavivirus genus of the family Flaviviridae. The ﬂavivirus
genus includes approximately 70 viruses of which there are
3 antigenic complexes; the Japanese encephalitis virus, tick-
borne encephalitis, and the dengue virus complexes [1].
Therearefourdistinctserotypesofdenguevirus(i.e.,dengue
virus serotypes 1–4) which all cause clinical disease. It is
estimated that more than 2.5 billion people are at risk of
infection and more than 100 countries have endemic dengue
virus transmission. While exact numbers of dengue virus
cases are not available, for the period 2000–2004, the annual
average was 925,896 cases, which was almost double when
compared to the 479,848 cases that were reported for the
period 1990–1999 [2]. About 250,000 to 500,000 cases of
DHF are reported annually although the true incidence is
not really known [3]. In dengue endemic regions which
include countries in Asia and the Americas, the burden of
dengue is approximately 1,300 disability-adjusted life years
(DALYs) per million population, which is similar to the
disease burden of other childhood and tropical diseases,
including tuberculosis, in these regions [2].
1.2. Why Do We Need Rapid Diagnostic Tests (RDTs) and
Who Controls the Quality? Laboratory tests are essential to
provideanaccuratediagnosisofacutedenguevirusinfection
atpatientpresentationtoaclinicalsettingsothatappropriate
treatment and patient management may be administered.
In many dengue endemic settings, laboratory diagnostic
resources are limited and simple rapid diagnostic tests
(RDTs) provide opportunities for point-of-care diagnosis.
The characteristics of the ideal diagnostic test are said to be
deﬁned by the ASSURED criteria: (1) Aﬀordable by those
at risk of infection; (2) Sensitive (few false-negatives); (3)
Speciﬁc (few false-positives); (4) User-friendly (simple to
perform and requiring minimal training); (5) Rapid (to
enable treatment at ﬁrst visit) and Robust (does not require
refrigerated storage); (6) Equipment-free; (7) Delivered to
those who need it [4].2 Journal of Biomedicine and Biotechnology
The need for simple point-of-care diagnostic tests has
led to the proliferation of antibody-based RDTs for trop-
ical infections such as dengue, leptospirosis, melioidosis,
and malaria using the immunochromatographic test (ICT)
format. Unfortunately, many dengue antibody-based RDTs
had substandard performance for the diagnosis of acute
dengue at patient presentation which leads to the large-scale
evaluations funded by independent international organi-
sations such as World Health Organization (WHO) [5,
6] to determine which are the best of the commercial
assays. Until these large-scale evaluations were performed,
many“backyard”manufacturersmarketedtheirproductsvia
the internet with little or no independent veriﬁcation of
the manufacturer’s performance claims. Results from these
evaluations have provided independent performance details
to consumers, and poor results challenged manufacturers to
improve RDT performance. The RDT market still remains
largely unregulated with the exception of the USA where
in vitro devices require approval by the Food and Drug
Administration (FDA) however, in the absence of national
regulations, high-quality, independent assessments in peer-
reviewed journals provide the best guide to quality.
1.3. Rapid Test Formats. Immunochromatographic tests for
the detection of dengue virus nonstructural protein 1 (NS1)
antigen, IgM, IgG, and IgA antibodies have been developed
by a number of commercial companies and have found
wide application because of their ease of use and rapidity
of results. These dengue RDTs are presented in the form
of a lateral ﬂow cassette that allows the ﬂow of sample in
a horizontal plane or a wick-style test that is performed
in a tube and draws sample vertically by capillary action.
D e n g u ev i r u sR D T su s eac o c k t a i lo fd r i e da n t i g e n sa n d
colloidal gold-labelled monoclonal antibodies (speciﬁc for
dengueNS1antigen,IgM,IgG,orIgAantibodies)onapadat
the head of a nitrocellulose strip which is impregnated with
either antidengue NS1 antigen, IgM, IgG, or IgA antibody
lines. Test sample and running buﬀer are added to the pad
which releases the colloidal gold from the pad and facilitates
the mixing of the patient sample with the gold complex
and facilitates the migration of the reagents and sample by
capillary action along the nitrocellulose strip towards the
anti-human IgM, IgG, or IgA antibody lines. The presence of
dengue virus NS1 antigen or IgM, IgG, or IgA antibodies is
signiﬁed by the development of maroon lines in the location
of the antibody lines. The dengue RDTs have the advantage
that they can be performed in approximately 10–15 minutes
and requires no specialized equipment or training, making
them ideal for low-technology environments; however, this
format has the weakness of subjective reading by the
operator.
1.4. Rapid Test Evaluation Methodologies. Diagnostic assays
are usually evaluated in terms of sensitivity and speciﬁcity
thatiscalculatedusinga2 ×2cross-tabulationwherea“gold
standard” result (the peer-acknowledged, most accurate test)
or reference standard result (normally, the test most widely
used)iscomparedwiththerapidtesttodeterminediagnostic
accuracy. A test that is 100% sensitive and speciﬁc is deemed
to be a perfect test. The choice of gold standard assay, ﬁnal
patient result, or comparison with nonreference assay as the
reference comparator can have a large inﬂuence on the ﬁnal
diagnostic accuracy results. Unfortunately, there is a lack
of conformity in the evaluation methodologies and choice
of reference assays for dengue RDT diagnostic assessments;
however, it should be noted that this issue is not conﬁned
only to dengue diagnostics. Guidelines for the evaluations
of dengue diagnostic assays have recently been published
[7] which is hoped will provide a framework for a uniform
approach to diagnostic assessments.
1.5. Dynamics of Dengue Virus Infection: Implications for
Diagnosis. The dynamics of dengue virus infection have a
potentially large inﬂuence on the interpretation of RDTs
(Figures 1 and 2). Following the initial infection, the dengue
virus replicates to high titers in the blood before patients
are unwell enough to present to a physician, with viraemia
peaking at the time or shortly after the onset of symptoms.
Virus remains detectable in the blood for up to 2 to 12
days after the onset of symptoms and may reach titers of
up to 1 × 108 50% infectious doses (ID50)p e rm Lo r
108.5 50% mosquito infectious doses (MID50)[ 8, 9]. During
the viraemic phase of dengue infection, NS1 antigen is
producedconcomitantlyduringthevirusreplicationprocess.
NS1 antigen is a 46- to 50-kilodalton glycoprotein highly
conserved by all dengue serotypes and is expressed in either
membrane-associated or secreted forms [10, 11]. Soluble
NS1 circulates in the serum of patients during the viraemic
phase of infection of dengue virus infections and hence is
an excellent diagnostic target for acute dengue diagnosis.
Diﬀerence in the persistence of soluble NS1 antigen in
serum between primary (5-6 days post-onset of illness) and
secondarydengueinfections(6–12days)hasbeen,notedand
it is hypothesised that the presence of anti-NS1 antibodies,
that are more frequently detected in dengue secondary
infection [12], modulates the formation of antibody-antigen
complexes which impede the ability of the test to detect free
NS1 antigen [13, 14].
An understanding of the features of the host humoral
immune responsetodenguevirusinfectionalsoisimportant
for the interpretation of dengue RDTs. Dengue IgM antibod-
iesareareliablemarkerofrecentinfectionbutnotnecessarily
acute infection. In primary dengue virus infections, IgM
antibodiesdevelopfollowingthedeclineofviraemiabetween
days 3–5 after the onset of infection using very sensitive
detection methods [15, 16] and reache peak levels approx-
imately 2 weeks later [17]. Persistence of IgM antibodies
following primary infection using linear regression method
has been estimated at 179 days (95% conﬁdence interval,
155 to 215 days) [18]. In dengue endemic settings where
in secondary infections dominate, IgM antibodies may be
detectable by RDTs as soon as after 2-3 days of infection
[19–21] and peak IgM antibody levels are usually lower than
in primary infections [8, 22]. Persistence of IgM antibodies
following secondary infection is estimated to be shorter than
that of primary infections at 139 days (95% conﬁdence
interval,119to167days)[18],andotherpublishedestimates
of IgM antibody persistence range from 2 months to 6Journal of Biomedicine and Biotechnology 3
Time (days) 
Antibody/antigen level 
NS1 
IgG
IgM
IgA
Viraemia
 
2468 1 0 1 2 1 4  
Figure 1: Graphical representation of the kinetics of dengue NS1
antigen and IgM, IgG, and IgA antibodies during a primary dengue
infection.
months [8, 23]. The IgG antibody response develops a few
days after the onset of the IgM antibody response and is
serotype speciﬁc and may persist for many years following a
single infection. Secondary dengue virus infections generate
ananamnesticIgGantibody responsethatischaracterisedby
a rapid rise in IgG antibodies detectable at days 4-5 of illness
[16] which is much sooner than the normal IgG antibody
response of a primary infection. Dengue IgA antibodies
have been reported in serum of dengue fever patients only
between days 8 and 11 after onset of fever [17]. However,
in the more severe forms of the disease, IgA antibodies were
reportedly undetectable in DHF patients in the acute phase
of illness (days 2 to 4) but increased in the following early
convalescent phase (days 5 to 14) and, in DSS patients,
increased to the highest levels on days 8 to 11 and slightly
decreased15daysafteronsetoffever[17].Inprimarydengue
infection, the onset of detectable levels of IgA antibodies has
been reported on average at 5.5 days after onset of fever,
and, in secondary infection, IgA antibodies increased slowly
during the ﬁrst days of the study [22]. The rates of positivity
for IgA antibodies in serum were reportedly signiﬁcantly
higher in secondary infections than in primary infections
(100 versus 84.6%) [24].
2.DiagnosticEvaluations
2.1. Performance of Antibody-Based Diagnostics. Dengue
IgM and IgG antibody-based RDTs have been in existence
for approximately 15 years in various forms by diﬀerent
manufacturers (see Table 1 for description of contemporary
commercial dengue IgM and IgG-based RDTs). Multiple
diagnostic evaluations were performed from the late 1990s
to the mid-2000s [25–29]; however, signiﬁcant heterogene-
ity in evaluation methodologies makes direct comparison
of diagnostic accuracy problematic [30]. In 2005, WHO
Western Paciﬁc Regional Oﬃce (WPRO) commissioned an
independentevaluationofdengueIgMRDTperformancefor
acute diagnosis as well as an evaluation of storage conditions
using stored samples from Thailand [6]a n dp r o s p e c t i v e l y
Time (days) 
Antibody/antigen level 
NS1 
IgG
IgM
IgA
Viraemia
 
2468 1 0 1 2 1 4  
Figure 2: Graphical representation of the kinetics of dengue NS1
antigen and IgM, IgG, and IgA antibodies during a secondary
dengue infection.
recruited patient samples from Lao PDR [31]. The results
for the majority of the evaluated dengue IgM antibody
RDTs demonstrated a lack of sensitivity for acute dengue
infection diagnosis that ranged from 6.4% to 65.3% and
speciﬁcities ranged from 69.1% to 100% (selected results
are presented in Table 2). Subsequently, WHO sponsored a
multicentre evaluation of dengue IgM antibody RDTs where
test sensitivities ranged from 21% to 99% and speciﬁcities
ranged from 77% to 98% when compared with reference
ELISAs [5]. Subsequent evaluations of the Panbio Duo IgM
RDT reported sensitivities ranging from 65.3 to 81.8% and
speciﬁcities ranging from 75.0 to 97.6% (Table 2). Recent
assessments of the Standard Diagnostics (SD) IgM RDT
demonstrated improved sensitivity compared to the very
poor 1st generation device results from the WHO study
[6] (21.8%), with 2nd generation device having reported
sensitivitiesof53.5%[21]and79.2%[19].Theimprovement
inthe2ndgenerationSDIgMRDTisevidenceofthepositive
feedback of diagnostic evaluations to the manufacturers.
2.2. Performance of NS1 Antigen-Based Diagnostics. The
mostimportantdevelopmentindenguediagnosticsinrecent
years is the advent of the speciﬁc detection of dengue virus
NS1 antigen (see Table 1 for description of contemporary
commercial dengue NS1 antigen RDTs). Dengue RDTs that
detect NS1 antigen employ a number of serotype-speciﬁc
anti-NS1 monoclonal antibodies to capture and detect
soluble NS1 antigen in serum, plasma, or blood. The ﬁrst
commercialassaysfordengueNS1antigendetectionusedthe
ELISAformat[14,36]anddemonstratedexcellentsensitivity
and speciﬁcity in the early phase of infection that dimin-
ished with falling viraemia levels. The major commercial
diagnostics manufacturers, Panbio, Biorad, and SD, have
all developed RDT-based NS1 antigen tests, and all have
equivalent ELISA-based assays. The diagnostic performance
of NS1-based RDTs from the abovementioned manufactur-
ers has been evaluated in numerous geographical locations
with the results from 21 diagnostic evaluations presented
in Table 3. Twelve studies evaluated the Biorad STRIP RDT4 Journal of Biomedicine and Biotechnology
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for the diagnosis of acute dengue infection using admission
samples,andtheresultsdemonstratedconsiderablevariation
in sensitivity (49.8%–98.7%) but the speciﬁcities reported
were more consistent with all being >90%. For 25% (3/12)
of the studies, the sensitivity was >8 9 % ;h o w e v e r ,a l lo f
these studies used a skewed comparator of either virus
isolation, RT-PCR, or NS1-ELISA and did not examine the
possibility of false-negative results by testing paired serum
samples to examine for dynamic rise in serological assays
such as IgM (MAC) or IgG (GAC) capture ELISAs. Studies
that used a more representative combination of virus or
antigen detection and serology as reference comparators
gave sensitivities for the Biorad STRIP RDT of between
49.4% [37] and 78.9% [38]. The SD Bioline Dengue Duo
RDT NS1 antigen detection strip was evaluated for acute
dengue diagnosis in four studies (Table 3) with consistently
high speciﬁcity estimates (96.7–100%) and sensitivities that
rangedfrom48.5%[19]to65.4%[21]withthestudieseither
using a combination of virus detection and serology [21,
39, 40] as comparators or serology alone [19]. The Panbio
Early Rapid RDT NS1 antigen detection strip was evaluated
in two studies using samples from three locations (Vietnam,
Malaysia, and Sri Lanka) with high speciﬁcity estimates
(92.5–96.7%) and sensitivities that ranged from 58.6% [19]
to 69.2% [20] for admission samples. A few studies have
compared the diagnostic accuracy of NS1 antigen RDTs in
primary and secondary dengue infections. Generally, NS1-
antigen RDTs demonstrated higher sensitivities in primary
infections when compared to secondary infections [39, 41–
43]; however, other studies have reported the opposite
[37]. As mentioned earlier, it has been suggested that this
phenomenon of lowered NS1-antigen detection in dengue
secondary infections is caused by NS1 antigen complexing
with anti-NS1 antibodies [12–14]. This observation results
in an inability of the NS1-antigen RDT to detect complexed
NS1 antigen and should not be interpreted insensitivity on
the part of the diagnostic assay.
2.3. Combination of NS1 Antigen and IgM Antibody Results.
To take advantage of the entire temporal spectrum of patient
presentation during the acute phase of dengue infection
(usually from 1 to 7 days after onset of fever), NS1
antigen and IgM antibody results have been combined in
a Boolean manner using AND/OR operators. NS1 antigen
is present in the serum in the early phase of infection;
however, patients that present late in the course of infection
may have undetectable levels of NS1 antigen. Dengue
IgM antibodies are usually present following 2–5 days of
infection, and, by combining the results of dengue NS1
antigen and IgM antibody testing, accurate diagnosis during
acute presentation is aﬀorded. This approach was initially
described [48] by combining the results of the Panbio NS1
antigenandIgMantibodyELISAsinLaoPDR.Subsequently,
studies [19–21] have combined NS1 antigen and antibody
results to exploit the temporal diagnostic characteristics of
each analyte (Table 4). Combining the SD Bioline Dengue
D u oR D TN S 1a n t i g e na n dI g Ma n t i b o d yr e s u l t sf o ra c u t e
diagnosis, the sensitivity ranged from 75.5% [39] to 92.9%
[19] and the speciﬁcity from 88.8% [19] to 100% [39].
Combining the Panbio Early Rapid RDT NS1 antigen and
IgM antibody results, the sensitivity ranged from 89.0% to
89.9%; the only speciﬁcity reported was 75.0% [19].
3. FutureNeeds for Dengue RapidTests
Despite recent improvements in the RDTs, there are a num-
ber of issues that require further investigation.
3.1. Standardisation of Diagnostic Assessments. The afore-
mentioned lack of conformity in the evaluation of dengue
RDTs remains a problem and a standardised approach must
be considered when performing diagnostic assessments so
that there is comparability between studies. The recently
publishedguidelinesfortheevaluationsofdenguediagnostic
assays [7] should be followed whenever possible.
3.2. Determining Geographical Variation and Practical Aspects
of Test Use. To further strengthen the current diagnos-
tic accuracy estimates, prospective recruitment studies are
required in diﬀerent dengue-endemic locations where there
are variations in dengue infection status (primary versus
secondary),daysofillness,andpriortopresentation.Further
studies are also required to examine some of the more
practical aspects of dengue RDT performance that includes
the inﬂuence of operator training, interoperator variation,
and ease of use of the assays. Where case-control studies
are to be performed using characterised archived samples,
consideration should also be given to the appropriateness of
thecompositionofdenguepatient(serotypes,daysofillness)
and non-dengue patient (other dengue-like fevers) cohorts.
3.3. Diﬀerentiation of Primary versus Secondary Dengue
Infections. Patientswithsecondaryorlaterdengueinfections
are considered to have an increased risk of the more severe
forms of the disease, and therefore the accurate detection of
primary and secondary at presentation to a clinical facility
may become a promising patient management tool. Some
manufacturers of antibody-based RDTs claim their assays
a r ea b l et od i ﬀerentiate primary and secondary dengue virus
infections using the following criteria: (1) acute primary
dengue virus infection deﬁned as an IgM-positive and
IgG-negative (IgM+/IgG−) result and (2) acute secondary
dengue virus infection deﬁned as IgM-positive and IgG-
positive (IgM+/IgG+) or IgM-negative and IgG-positive
(IgM−/IgG+) results. Examination of the voracity of the
manufacturer’s claims is limited to a few studies [6, 19,
31] and is often conducted in dengue endemic settings
where there a dominance of secondary dengue infections.
Such studies have demonstrated that RDTs cannot reliably
diﬀerentiate the diﬀerent dengue infection states.
3.4. Sample Type and the Eﬀect of Anticoagulants and Preser-
vatives. Manymanufacturersallowtheuseofserum,plasma,
or whole blood (Table 1) for use in dengue RDTs in both
antigen and antibody formats. Interestingly, the Panbio Duo
antibodyRDTsonlypermitstheuseofserum.Unfortunately,
there is little quantitative evidence that all sample typesJournal of Biomedicine and Biotechnology 7
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perform equally and it is incumbent of manufacturers to
provide these performance details. The eﬀect of sample
anticoagulants and whole blood on RDT performance and
ease of reading also require examination in a ﬁeld setting.
3.5. Storage Considerations. Dengue endemic regions are
normally located in tropical regions that have high tempera-
ture and high humidity climates. Many of the contemporary
dengue rapid tests require refrigeration (i.e., 2–8◦C) (see
Table 1); however, some manufacturers specify storage at 2–
30◦C; however, ambient tropical temperatures often exceed
30◦C.Thereisanurgentneedtoexaminetheeﬀectofstorage
temperature on contemporary dengue RDTs as the only
previous investigation concentrated on earlier-generation
antibody-based tests [6].
3.6. Prognostic Markers of Disease Severity. While the acute
diagnosis of dengue infection is clinically useful, in a
dengue endemic setting where the majority of infections
are seen in outpatient settings, there is a clear need to
also have prognostic details of disease severity. The more
severe forms of dengue infection (DHF and DSS) require
patient admission to hospital and critical care facilities,
and prognostic indicators of clinical severity would provide
direction for patient management. Quantifying secreted NS1
antigen has been hypothesised as a marker of disease severity
[14], and subsequent studies have shown that dengue NS1
antigen levels correlate with severity disease where plasma
levels of secreted NS1 correlated with viraemia levels and
were higher in patients with DHF than in those with the
clinically less-severe dengue fever [13, 49].
4. Conclusions
Despite improvements in the accuracy of IgM-based RDTs,
t h i sf o r m a ti sn o ts u ﬃciently sensitive for acute dengue
diagnosis alone. Acute dengue diagnosis using IgG-based
RDTs is not recommended due to the lifelong persistence
of dengue IgG antibodies and hence the possibility of
misdiagnosis by false-positive detection. NS1-antigen-based
diagnostics are an important component of modern point
of care diagnostics; however, they are only sensitive in
the early phase of infection and therefore are not suitable
for sole use in dengue-endemic settings where late clinical
presentations may occur. To take advantage of the results
of testing modalities across the entire temporal spectrum of
patientpresentation,dengueNS1antigen,andIgMantibody,
RDT results must be combined; however, there is a need to
educate clinicians and scientists of this fact. The challenge
for manufacturers and researchers is to address the gaps
in the more practical aspects of dengue RDT performance
including samples types, RDT storage, disease severity, and
conduct of future diagnostic assessments.
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